Oncobiologics (OTLK) News Today $1.11 -1.27 (-53.45%) As of 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock OTLK Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 Time Period US FDA declines to approve Outlook Therapeutics' drug for eye conditionAugust 28 at 6:39 AM | reuters.comOutlook Therapeutics Provides Regulatory Update on U.S. Food and Drug Administration Review of ONS-5010/LYTENAVA™ (bevacizumab-vikg) for the Treatment of Wet AMDAugust 28 at 6:30 AM | globenewswire.comOutlook Therapeutics: Why The Odds Point To A Favorable FDA DecisionAugust 24, 2025 | seekingalpha.comOncobiologics FY2025 EPS Forecast Raised by HC WainwrightAugust 22, 2025 | marketbeat.comOncobiologics FY2025 EPS Estimate Increased by HC WainwrightAugust 22, 2025 | americanbankingnews.comOncobiologics (NASDAQ:OTLK) Releases Earnings Results, Misses Estimates By $0.02 EPSAugust 18, 2025 | marketbeat.comOncobiologics (NASDAQ:OTLK) Earns Neutral Rating from Chardan CapitalAugust 17, 2025 | marketbeat.comOncobiologics (NASDAQ:OTLK) Given "Neutral" Rating at Chardan CapitalAugust 17, 2025 | americanbankingnews.comOutlook Therapeutics Reports Financial Results for Third Quarter Fiscal Year 2025 and Provides Corporate UpdateAugust 14, 2025 | globenewswire.comOncobiologics (OTLK) Projected to Post Quarterly Earnings on WednesdayAugust 7, 2025 | marketbeat.comOncobiologics, Inc. (NASDAQ:OTLK) Given Average Recommendation of "Moderate Buy" by BrokeragesAugust 5, 2025 | marketbeat.comOncobiologics (NASDAQ:OTLK) Trading Down 1.5% - Should You Sell?August 3, 2025 | marketbeat.comOutlook Therapeutics to Present at the 8th Annual Ophthalmology Innovation Summit (OIS) Retina Innovation ShowcaseJuly 24, 2025 | globenewswire.comOutlook Therapeutics Participates in the Virtual Investor “What's Your Story” Summer Spotlight On-Demand ConferenceJuly 22, 2025 | globenewswire.comOncobiologics, Inc. (NASDAQ:OTLK) Given Average Recommendation of "Moderate Buy" by AnalystsJuly 11, 2025 | marketbeat.comOncobiologics (NASDAQ:OTLK) Trading Up 4.5% - Still a Buy?July 8, 2025 | marketbeat.comOTLK Outlook Therapeutics, Inc. - Seeking AlphaJuly 2, 2025 | seekingalpha.comOutlook Therapeutics Appoints Biopharmaceutical Industry and Commercial Leader Bob Jahr as Chief Executive OfficerJuly 1, 2025 | globenewswire.comOutlook Therapeutics to Participate in a Virtual Investor Lunch Break EventJune 18, 2025 | globenewswire.comOutlook Therapeutics, Inc. (NASDAQ:OTLK) Receives Average Recommendation of "Moderate Buy" from AnalystsJune 16, 2025 | marketbeat.comCFA Institute 2025 Graduate Outlook Survey: Finance Top Career ChoiceJune 12, 2025 | tmcnet.comSteve Wilks Pleased With Jets Defensive OutlookJune 12, 2025 | msn.comOutlook Therapeutics, Inc.: Outlook Therapeutics Announces SMC Recommendation of LYTENAVA (bevacizumab gamma) for the Treatment of Wet AMDJune 10, 2025 | finanznachrichten.deOutlook Therapeutics® Announces SMC Recommendation of LYTENAVA™ (bevacizumab gamma) for the Treatment of Wet AMDJune 10, 2025 | globenewswire.comOilers' Connor McDavid Offers Hilarious Outlook on Crucial Game 1 MomentJune 7, 2025 | msn.comChatGPT Business Features Now Include Gmail/Outlook Connectors, Meeting Transcriptions, New PricingJune 7, 2025 | techrepublic.comTOutlook Therapeutics (NASDAQ:OTLK) Given New $21.00 Price Target at Ascendiant Capital MarketsJune 6, 2025 | marketbeat.comOutlook Therapeutics® Announces Commercial Launch of LYTENAVA™ (bevacizumab gamma) in Germany and the UK for the Treatment of Wet AMDJune 2, 2025 | globenewswire.comQ3 EPS Estimate for Outlook Therapeutics Boosted by AnalystMay 31, 2025 | marketbeat.comBrookline Capital Management Forecasts OTLK FY2026 EarningsMay 30, 2025 | marketbeat.comOutlook Therapeutics, Inc. (NASDAQ:OTLK) Given Consensus Rating of "Moderate Buy" by AnalystsMay 24, 2025 | marketbeat.comOutlook Therapeutics announces public stock offeringMay 24, 2025 | investing.comOutlook Therapeutics, Inc. Announces Underwritten Public Offering of Common Stock and WarrantsMay 24, 2025 | nasdaq.comOutlook Therapeutics announces proposed public offering of common stock, warrantsMay 23, 2025 | msn.comOutlook Therapeutics drops 17%, prices $13M stock offeringMay 23, 2025 | msn.comOutlook Therapeutics® Announces Pricing of $13.0 Million Public OfferingMay 23, 2025 | globenewswire.comOutlook Therapeutics® Announces Proposed Public Offering of Common Stock and WarrantsMay 22, 2025 | globenewswire.comTang Capital Management LLC Has $345,000 Stake in Outlook Therapeutics, Inc. (NASDAQ:OTLK)May 21, 2025 | marketbeat.comOutlook Therapeutics, Inc.: Outlook Therapeutics Reports Financial Results for Second Quarter Fiscal Year 2025 and Provides Corporate UpdateMay 16, 2025 | finanznachrichten.deOutlook Therapeutics (OTLK) Projected to Post Quarterly Earnings on WednesdayMay 16, 2025 | marketbeat.comOutlook Therapeutics Reports Financial Results for Second Quarter Fiscal Year 2025 and Provides Corporate UpdateMay 15, 2025 | globenewswire.comWant to use both new and classic Outlook apps? Soon, says MicrosoftMay 7, 2025 | msn.comOutlook Therapeutics announces acceptance of BLA by U.S. FDA for ONS-5010April 8, 2025 | markets.businessinsider.comOutlook Therapeutics® Announces Acceptance of Biologics License Application by U.S. FDA for ONS-5010 as a Treatment for Wet AMDApril 8, 2025 | globenewswire.comOutlook Therapeutics management to meet virtually with BTIGMarch 21, 2025 | markets.businessinsider.comOutlook Therapeutics files to sell 21.72M shares of common stock for holdersMarch 21, 2025 | markets.businessinsider.comOutlook Therapeutics expands share authorizationMarch 16, 2025 | investing.comOutlook Therapeutics Issues Convertible Note to AvondaleMarch 14, 2025 | tipranks.comOutlook Therapeutics files to sell 7.07M shares of common stock for holdersMarch 1, 2025 | markets.businessinsider.comOutlook Therapeutics® Re-Submits Biologics License Application for ONS-5010 as a Treatment for Wet AMD to the U.S. Food and Drug AdministrationFebruary 28, 2025 | globenewswire.com Get Oncobiologics News Delivered to You Automatically Sign up to receive the latest news and ratings for OTLK and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. OTLK Media Mentions By Week OTLK Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. OTLK News Sentiment▼1.200.99▲Average Medical News Sentiment OTLK News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. OTLK Articles This Week▼73▲OTLK Articles Average Week Get the Latest News and Ratings for OTLK and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Oncobiologics and its competitors. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies Zevra Therapeutics News Today Opthea News Today Alumis News Today aTyr Pharma News Today Kodiak Sciences News Today Bicycle Therapeutics News Today Arcturus Therapeutics News Today Evolus News Today Prime Medicine News Today Nanobiotix News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:OTLK) was last updated on 8/28/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredWhat Steve Bannon revealed about Trump’s gold playA Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...Reagan Gold Group | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredTake a look at this picture ...A strange investment secret — discovered just a few short weeks before this image was taken — correctly predic...Weiss Ratings | SponsoredThink you missed gold’s boom? Think againIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Oncobiologics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Oncobiologics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access